Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fid-007
- Development stage
- Phase 2
- Lead developer
- Fulgent Pharma
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
FID-007 is a **novel nanoencapsulated formulation of paclitaxel**, encapsulated within a polyethyloxazoline (PEOX) polymer using nano-drug delivery technology. Its design aims to improve pharmacokinetics, tissue biodistribution, and tolerability by targeting tumors' leaky vasculature, thereby delivering paclitaxel directly to cancer cells. Preclinical studies demonstrated enhanced anti-tumor activity and reduced neuropathy versus traditional taxanes. FID-007 is developing as a cancer treatment, currently evaluated for advanced solid tumors, with a primary focus on head and neck squamous cell carcinoma (HNSCC), pancreatic, breast, and non-small cell lung cancers[1][3][4][6][8].
- Other names
- FID-007FID007FID 007peox-based polymer encapsulated paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on fid-007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fid-007.